Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ER2001 in Early Manifest Huntington's Disease
NCT07344519Phase 1Completed
- Sponsor
- ExoRNA Bioscience
- Start
- Jun 2024
- Primary completion
- Jun 2025
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ER2001 in Huntington's disease (HD), sponsored by ExoRNA Bioscience. Primary endpoint: Incidence and Severity of adverse events (AEs) and serious adverse events (SAEs) at 4.5 months. Started Jun 2024; status: completed.
02
Drugs
ER2001
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT07344519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07344519.